These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 36314826)

  • 1. Long-Lasting Protection Induced by a Polyanhydride Nanovaccine against Respiratory Syncytial Virus in an Outbred Mouse Model.
    Stephens LM; Ross KA; McLellan JS; Narasimhan B; Varga SM
    J Virol; 2022 Nov; 96(22):e0150222. PubMed ID: 36314826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prefusion F-Based Polyanhydride Nanovaccine Induces Both Humoral and Cell-Mediated Immunity Resulting in Long-Lasting Protection against Respiratory Syncytial Virus.
    Stephens LM; Ross KA; Waldstein KA; Legge KL; McLellan JS; Narasimhan B; Varga SM
    J Immunol; 2021 May; 206(9):2122-2134. PubMed ID: 33827894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative Virus-Like Particle-Associated Prefusion F Proteins as Maternal Vaccines for Respiratory Syncytial Virus.
    Blanco JCG; Fernando LR; Zhang W; Kamali A; Boukhvalova MS; McGinnes-Cullen L; Morrison TG
    J Virol; 2019 Dec; 93(23):. PubMed ID: 31511382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parainfluenza Virus 5 Expressing Wild-Type or Prefusion Respiratory Syncytial Virus (RSV) Fusion Protein Protects Mice and Cotton Rats from RSV Challenge.
    Phan SI; Zengel JR; Wei H; Li Z; Wang D; He B
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28747496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV.
    Liang B; Matsuoka Y; Le Nouën C; Liu X; Herbert R; Swerczek J; Santos C; Paneru M; Collins PL; Buchholz UJ; Munir S
    J Virol; 2020 Dec; 95(2):. PubMed ID: 33115876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Respiratory Syncytial Virus Vaccine Vectored by a Stable Chimeric and Replication-Deficient Sendai Virus Protects Mice without Inducing Enhanced Disease.
    Wiegand MA; Gori-Savellini G; Gandolfo C; Papa G; Kaufmann C; Felder E; Ginori A; Disanto MG; Spina D; Cusi MG
    J Virol; 2017 May; 91(10):. PubMed ID: 28250126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of an adenovirus-based respiratory syncytial virus vaccine: preclinical evaluation of efficacy, immunogenicity, and enhanced disease in a cotton rat model.
    Kim E; Okada K; Beeler JA; Crim RL; Piedra PA; Gilbert BE; Gambotto A
    J Virol; 2014 May; 88(9):5100-8. PubMed ID: 24574396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats.
    Widjojoatmodjo MN; Bogaert L; Meek B; Zahn R; Vellinga J; Custers J; Serroyen J; Radošević K; Schuitemaker H
    Vaccine; 2015 Oct; 33(41):5406-5414. PubMed ID: 26319741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal immunization with a helper-dependent adenoviral vector expressing the codon-optimized fusion glycoprotein of human respiratory syncytial virus elicits protective immunity in BALB/c mice.
    Fu YH; He JS; Qiao W; Jiao YY; Hua Y; Zhang Y; Peng XL; Hong T
    Virol J; 2013 Jun; 10():183. PubMed ID: 23742026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal immunization with a single dose of the fusion protein formulated with a combination adjuvant induces long-term protective immunity against respiratory syncytial virus.
    Garg R; Latimer L; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
    Hum Vaccin Immunother; 2017 Dec; 13(12):2894-2901. PubMed ID: 28825870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
    Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
    Gilbert BE; Patel N; Lu H; Liu Y; Guebre-Xabier M; Piedra PA; Glenn G; Ellingsworth L; Smith G
    Vaccine; 2018 Dec; 36(52):8069-8078. PubMed ID: 30389195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles.
    Rigter A; Widjaja I; Versantvoort H; Coenjaerts FE; van Roosmalen M; Leenhouts K; Rottier PJ; Haijema BJ; de Haan CA
    PLoS One; 2013; 8(8):e71072. PubMed ID: 23951084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
    Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM
    Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells.
    Kim KH; Lee YT; Hwang HS; Kwon YM; Kim MC; Ko EJ; Lee JS; Lee Y; Kang SM
    J Virol; 2015 Nov; 89(22):11692-705. PubMed ID: 26355098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults.
    Green CA; Sande CJ; Scarselli E; Capone S; Vitelli A; Nicosia A; Silva-Reyes L; Thompson AJ; de Lara CM; Taylor KS; Haworth K; Hutchings CL; Cargill T; Angus B; Klenerman P; Pollard AJ
    J Infect; 2019 May; 78(5):382-392. PubMed ID: 30742894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and characterization of a fusion glycoprotein vaccine for Respiratory Syncytial Virus with improved stability.
    Zhang L; Durr E; Galli JD; Cosmi S; Cejas PJ; Luo B; Touch S; Parmet P; Fridman A; Espeseth AS; Bett AJ
    Vaccine; 2018 Dec; 36(52):8119-8130. PubMed ID: 30340881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization.
    Raghunandan R; Lu H; Zhou B; Xabier MG; Massare MJ; Flyer DC; Fries LF; Smith GE; Glenn GM
    Vaccine; 2014 Nov; 32(48):6485-92. PubMed ID: 25269094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate.
    Liang B; Ngwuta JO; Surman S; Kabatova B; Liu X; Lingemann M; Liu X; Yang L; Herbert R; Swerczek J; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Collins PL; Munir S
    J Virol; 2017 Aug; 91(15):. PubMed ID: 28539444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delta inulin-derived adjuvants that elicit Th1 phenotype following vaccination reduces respiratory syncytial virus lung titers without a reduction in lung immunopathology.
    Wong TM; Petrovsky N; Bissel SJ; Wiley CA; Ross TM
    Hum Vaccin Immunother; 2016 Aug; 12(8):2096-2105. PubMed ID: 27215855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.